Objective: Our study describes a typical case of New Daily Persistent Headache (NDPH), refractory to different therapies, that presented a satisfactory response to repeated cycles of botulinum toxin type A. Background: New Daily Persistent Headache is a primary headache disorder, characterized by chronic and unremitting daily headache with abrupt onset and more than three months in duration. It lacks typical clinical features, being similar to chronic migraine without aura or tension-type headache. It may be self-limiting within months or years without therapy, or be refractory to most treatments. Case Report: A 56-year-old woman suffered since eleven years from a daily and continuous headache, pressing/tightening in quality and of moderate intensity, but with daily paroxysms of stabbing pain, without autonomic symptoms. No trigger factors of pain were detected. She experienced a remission period of three years, after that the pain relapsed with the same features. Neurological examination was negative, apart from minimal dysarthria. She was submitted to various examinations (including a complete psychiatric evaluation) and finally diagnosed as NDPH. Her pain was unresponsive to multiple pharmacological treatments. Results: After a week from first cycle of botulinum toxin type A (195 U) she experienced a satisfactory relief of pain and good improvement of her quality of life. Her pain relapsed shortly before subsequent administration of Botox and after a missed cycle: a good relief was subsequently obtained with further cycles of the treatment. Conclusions: This is our second case of NDPH successfully treated with Botulinum Toxin type A. We propose this treatment for refractory cases of chronic daily headaches, including NDPH.
Introduction
New Daily Persistent Headache (NDPH) is a primary headache disorder, characterized by sudden onset (clearly remembered by the patient), followed by chronic and unremitting daily headache within 24 hours, lasting more than three months. It was first described by Vanast [1] in 1986 and later clinically better characterized [2] . It lacks typical clinical features, the pain being suggestive of chronic migraine without aura or tension-type headache. A percentage of NDPH sufferers may report some precipitating events such as a flu-like illness, surgical interventions or stressful events [3] . It may be self-limiting within months or years without therapy, or be refractory to most treatments, frequently representing a major therapeutic challenge.
The pathogenesis of NDPH is unknown, but in some cases association with viral infections and elevation of CSF Tumor Necrosis Factor α (TNFα) levels, a pro-inflammatory cytokine involved in brain immune and inflammatory processes [4] , were reported. A pathogenetic hypothesis is a Central Nervous System (CNS) inflammation, triggered by a viral infection. One paper described a widespread joint hypermobility, specifically in the cervical spine, as a predisposing factor for the development of NDPH [5] . In Table 1 diagnostic criteria from the International Classification of Headache Disorders, 3 rd Edition is reported.
We describe a case of NDPH, refractory to different treatments, who after first administration of botulinum toxin type A (195 U) presented a satisfactory remission of pain. were performed.
Case Report
The pain was refractory to various symptomatic drugs, including NSAIDs and acetaminophen (at the time of first visit she did not take any symptomatic treatment). As prophylactics, she was treated with anti-depressive drugs as amytriptiline, sertraline, duloxetine, all ineffective; also topiramate, acetylsalicylic acid, and later cycles of oral steroids and verapamil were prescribed without success.
After informed consent, she was treated with botulinum toxin type A (Botox) 195 U s. c. since November 2017, with cycles every three months, following PREEMPT sites of injection and dose paradigm for chronic migraine plus follow-the-pain pattern [6] . The pain relieved about a week after first cycle and relapsed with very mild intensity (VAS 1 -2) about five-seven days before subsequent administration of Botox (the same also for second and third cycle 
Discussion
The clinical features of headache, with clearly remembered onset and subsequent continuous pattern (apart from a spontaneous remission after a head trauma), with characteristics of tension-type headache but with stabbing paroxysms, the substantial normality of clinical and instrumental examinations and the refractoriness to most therapies were in accordance with a diagnosis of NDPH (maybe a relapsing-remitting form). A specific trigger factor for the onset of the headache could not be determined.
This is our second case of NDPH treated with botulinum toxin type A. We postulated possible efficacy of the treatment on the basis of some similarities between clinical presentation of NDPH and chronic migraine and of the reported quick responsiveness of this headache entity in a single case, at the dose of 100 units for three cycles of therapy [7] , and other unpublished cases.
We confirmed these observations with our previous case report [8] . In the present case we can reasonably exclude a spontaneous remission of the headache because of the relapse of less severe pain after one missed cycle of Botox.
Botulinum toxin type A was the only effective treatment and strongly contrib- 
Conclusion
We believe our cases could represent a further stimulus to perform more observations (i.e. randomized controlled prospective studies) on the efficacy of botulinum toxin type A therapy in chronic refractory primary headaches, including NDPH, in view of the inclusion in national and international therapeutic guidelines.
Consent
The patient expressed in writing informed consent to the publications of data 
